AIM Rules

The information contained within this section is for purposes of AIM Rule 26.
Last updated: 18 April 2019

Description of the business:

To see the Company’s description of the business, please click here

Board of Directors and biographical details:

To see the names of the Company’s Directors, their biographical details and their responsibilities, please click here

Corporate Governance:

To see information on the Company’s Corporate Governance, please click here

Board committees:

To see the Company’s Board Committees and the list of members in these committees, please click here

Country of incorporation and main country of operation:

The Company was incorporated in the United Kingdom in 2006, and is based in Leeds. Tissue Regenix’s main country of operation is the United Kingdom, but it also has an operation in Texas, United States of America.

The Company is subject to the United Kingdom’s City Code on Takeovers and Mergers.

Current constitutional documents:

To see the Company’s reports & documents, please click here

Number of securities in issue:

Shares not in public hands as at 19 February 2019 – 856,002,530 - 73%

Shares in issue as at 19 February 2019 - 1,171,730,823 ordinary shares of 0.5p each

Identity and percentage holdings of significant shareholders:

To see the Company’s significant shareholders list, please click here

Company announcements and notifications:

To see all notifications made by the Company in the past 12 months, please click here

Admission Document and circulars:

To see the Company’s reports & documents, please click here


To see the Company’s advisers, please click here